Supplier Qualification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Supplier Qualification
A comparison of comprehensive third-party excipient GMP audit programs.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 124-127

Conclusion

It is apparent that many generic manufacturers and smaller pharmaceutical companies use means other than physical audit to qualify their suppliers. An ANSI accredited certification program, therefore, is particularly useful because the program has been qualified by ANSI and can be so recognized by government agencies. An ANSI accredited certification program, furthermore, allows pharmaceutical companies to use certification in lieu of site audit for supplier qualification.

Assuring the safety of the drug supply has modified the development of each of these programs. FDA has explicitly stated at meetings and presentations that shared-audit and third-party audit programs are acceptable as part of a supplier qualification program (5). Continuing reports of economically motivated adulteration reminds the industry that each site supplying excipients must be physically audited to ensure conformance to GMP requirements. Supply chain security must begin with a site audit.

Participation by an excipient supplier in any one program can provide adequate assurance of the conformance of the excipient to GMP because the basis of the audit is the well accepted IPEC-PQG GMP Guide for Pharmaceutical Excipients. As described herein, the Rx–360, EXCiPACT, and IPEA programs each exercise great care in the selection, training, and qualification of their auditors. FDA has informally stated that these schemes meet regulatory expectations because they have addressed the issue of auditor competency as a core part of the audit process. Thus the schemes can provide the excipient user with a high degree of assurance that excipient from suppliers that have participated in a program meet cGMP expectations and will continue to do so. The cost barrier for this assurance can be greatly reduced by these programs.

These schemes, therefore, can help to ensure patient safety when the drugs that patients consume have been formulated with excipient components supplied by manufacturers whose facilities have been audited.

Darcy Ewalt is director of divisional GMP auditing at Merck Sharp & Dohme, Corp. (Merck is a member of Rx–360). Tracy L. Cooper, Johnson & Johnson, AD, Consumer Regulatory Compliance (J&J is a member of Rx–360). Frithjof Holtz is quality and regulatory management head of MM-QS Advocacy (EXCiPACT) at Merck Millipore. Irwin Silverstein is vice-president and chief operating officer of International Pharmaceutical Excipients Auditing, Inc.

References

1. I. Silverstein, Pharm. Technol. 33 (10), 84–88 (2009).

2. FDA, Advisory to Drug and Dietary Supplement Manufacturers, Compounding Pharmacies and Distributors of Excipients and Dietary Ingredients-FDA Detects High Levels of Peroxide in Crospovidone (Oct. 21, 2010), http://www.fda.gov/Drugs/DrugSafety/ucm230492.htm

3. B. Hasselbalch, "Public Health Challenges for the Quality of Human Drugs," presented at FDA-Xavier University Global Outsourcing Conference (Cincinnati, June 2010).

4. The Falsified Medicines Directive (FMD) 201⅙2/EU, http://ec.europa.eu/health/files/eudralex/...2011_62/dir_2011_62_en.pdf.

5. See FDA and MHRA presentations at the EXCiPACT launch event in 2012 which are hosted on the EXCiPACT website at http://www.excipiact.org/.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here